Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 3/2008

01-06-2008

C-Reactive Protein is Linked to Lower Cognitive Performance in Overweight and Obese Women

Authors: V. Sweat, V. Starr, H. Bruehl, A. Arentoft, A. Tirsi, E. Javier, A. Convit

Published in: Inflammation | Issue 3/2008

Login to get access

Abstract

Our objective was to ascertain the nature of the associations between C-reactive protein (CRP) and cognition, and to examine how they are affected by gender and obesity. We evaluated 62 females and 63 males between 42 and 82 years of age. There were 20 lean females with a body mass index (BMI) of <25 kg/m2 and 42 overweight or obese females, with BMIs ≥25 kg/m2. There were 14 lean males and 49 with BMIs ≥25 kg/m2. CRP was associated with lower scores on cognitive tests of frontal lobe function among females and these associations were driven by the overweight/obese female group. In these data no associations between CRP and cognition were found among males. Obesity-associated inflammation is much more prominent in females and it appears to be associated with cognitive dysfunction, particularly of frontal lobe tasks.
Literature
1.
Lee, W.-Y., J.-S. Park, S.-Y. Noh, E.-J. Rhee, K.-C. Sung, B.-S. Kim, J.-H. Kang, S.-W. Kim, M.-H. Lee, and J.-R. Park. 2004. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int. J. Cardiol. 97:101–106.PubMedCrossRef
2.
Wang, Z., and W. E. Hoy. 2007. C-reactive protein and the risk of developing type 2 diabetes in Aboriginal Australians. Diabetes Res. Clin. Pract. 76:37–43.PubMedCrossRef
3.
Han, T., C. Gonzalez-Villalpando, N. Sattar, M. Lean, K. Williams, and S. M. Haffner. 2007. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25(11):2016–2021.CrossRef
4.
Pearson, T. A., G. A. Mensah, R. W. Alexander, J. L. Anderson, R. O. Cannon III, M. Criqui, Y. Y. Fadl, S. P. Fortmann, Y. Hong, G. L. Myers, N. Rifai, S. C. Smith Jr., K. Taubert, R. P. Tracy, and F. Vinicor. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3):499–511 (Jan).PubMedCrossRef
5.
Kushner, I., D. Rzewnicki, and D. Samols. 2006. What does minor elevation of C-reactive protein signify? Am. J. Med. 119:166.e17–166.e28.CrossRef
6.
Swanson, S. J., M. M. McPeek, and R. F. Mortensen. 1989. Characteristics of the binding of human C-reactive protein (CRP) to laminin. J. Cell Biochem. 40(1):121–132 (May).PubMedCrossRef
7.
Pepys, M. B., and M. L. Baltz. 1983. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol. 34:141–212.PubMedCrossRef
8.
Haffner, S. M. 2006. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol. 97(2, Supplement 1):3–11 (Jan).CrossRef
9.
Parikh, N. I., M. J. Pencina, T. J. Wang, K. J. Lanier, C. S. Fox, R. B. D’Agostino, and R. S. Vasan. 2007. Increasing trends in incidence of overweight and obesity over 5 decades. Am. J. Med. 120(3):242–250 (Mar).PubMedCrossRef
10.
Ye, X., Z. Yu, H. Li, O. H. Franco, Y. Liu, and X. Lin. 2007. Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J. Am. Coll. Cardiol. 49(17):1798–1805 (May).PubMedCrossRef
11.
Florez, H., S. Castillo-Florez, A. Mendez, P. Casanova-Romero, C. Larreal-Urdaneta, D. Lee, and R. Goldberg. 2006. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res. Clin. Pract. 71(1):92–100 (Jan).PubMedCrossRef
12.
Wasir, J. S., A. Misra, N. K. Vikram, R. M. Pandey, and K. Luthra. 2007. C-reactive protein, obesity, and insulin resistance in postmenopausal women in urban slums of North India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 1(2):83–89 (Jun).CrossRef
13.
Thorand, B., J. Baumert, A. Doring, C. Herder, H. Kolb, W. Rathmann, G. Giani, and W. Koenig. 2006. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 184(1):216–224 (Jan).PubMedCrossRef
14.
Rexrode, K. M., A. Pradhan, J. E. Manson, J. E. Buring, and P. M. Ridker. 2003. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann. Epidemiol. 13(10):674–682 (Nov).PubMedCrossRef
15.
Lear, S., M. Chen, C. L. Birmingham, and J. J. Frohlich. 2003. The relationship between simple anthropometric indices and C-reactive protein: ethnic and gender differences. Metabolism 52(12):1542–1546.PubMedCrossRef
16.
Khera, A., D. McGuire, S. Murphy, H. Stanek, S. Das, W. Vongpatanasin, F. Wians, S. Grundy, and J. de Lemos. 2005. Race and gender differences in C-reactive protein levels. J. Am. Coll. Cardiol. 46(3):464–469.PubMedCrossRef
17.
Pieroni, L., J. P. Bastard, A. Piton, L. Kalil, B. Hainique, and C. Jardel. 2003. Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. Diabetes Metab. 29:133–138.PubMedCrossRef
18.
Kraus, V. B., T. V. Stabler, G. Luta, J. B. Renner, A. D. Dragomir, and J. M. Jordan. 2007. Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarth. Cartil. 15(8):966–971 (Aug).CrossRef
19.
Lakoski, S., M. Cushman, M. Criqui, T. Rundek, R. Blumenthal, R. B. D’Agostino, and D. Herrington. 2006. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am. Heart J. 152(3):593–598.PubMedCrossRef
20.
Kluft, C. 2002. HRT effects on inflammatory markers: is chronic inflammation a contra-indication for HRT? Int. Congr. Ser. 1229:103–108.CrossRef
21.
Abdullah, S. M., A. Khera, D. Leonard, S. R. Das, R. M. Canham, S. A. Kamath, G. L. Vega, S. M. Grundy, D. K. McGuire, and J. A. de Lemos. 2007. Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. Atherosclerosis 195(2):404–410 (Dec).PubMedCrossRef
22.
Ferrannini, E., A. Natali, P. Bell, P. Cavallo-Perin, N. Lalic, and G. Mingrone. 1997. Insulin resistance and hypersecretion in obesity. J. Clin. Invest. 100(5):1166–1173 (Sep).PubMedCrossRef
23.
Smith, D. O., and D. LeRoith. 2004. Insulin resistance syndrome, pre-diabetes, and the prevention of type 2 diabetes mellitus. Clin. Cornerstone 6(2):7–13.PubMedCrossRef
24.
Biessels, G.-J., E. ter Braak, D. Erkelens, and R. Hijman. 2001. Cognitive function in patients with type 2 diabetes mellitus. Neurosci. Res. Commun. 28(1):11–22.CrossRef
25.
Akisaki, T., T. Sakurai, T. Takata, H. Umegaki, A. Araki, S. Mizuno, S. Tanaka, Y. Ohashi, A. Iguchi, K. Yokono, and H. Ito. 2006. Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab. Res. Rev. 22(5):376–384.PubMedCrossRef
26.
Strachan, M., I. Deary, F. Ewing, and B. Frier. 1997. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 20(3):438–445.PubMedCrossRef
27.
Vanhanen, M., K. Koivisto, L. Karjalainen, E. L. Helkala, M. Laakso, H. Soininen, and P. Riekkinen, Sr. 1997. Risk for non-insulin-dependent diabetes in the normoglycaemic elderly is associated with impaired cognitive function. NeuroReport. 8(6):1527–1530.PubMedCrossRef
28.
Convit, A. 2005. Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol. Aging 26(1, Supplement 1):31–35 (Dec).PubMedCrossRef
29.
Gold, S. M., I. Dziobek, V. Sweat, A. Tirsi, K. Rogers, H. Bruehl, W. Tsui, S. Richardson, E. Javier, and A. Convit. 2007. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 50(4):711–719.PubMedCrossRef
30.
Convit, A., O. T. Wolf, C. Tarshish, and M. J. de Leon. 2003. Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc. Natl. Acad. Sci. U. S. A. 100(4):2019–2022.PubMedCrossRef
31.
Gunstad, J., R. H. Paul, R. A. Cohen, D. F. Tate, M. B. Spitznagel, and E. Gordon. 2007. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr. Psychiatry 48(1):57–61.PubMedCrossRef
32.
Weisell, R. C. 2002. Body mass index as an indicator of obesity. Asia Pac. J. Clin. Nutr. 11(Suppl 8):S681–S684.CrossRef
33.
Jeong, S. K., H. S. Nam, M. H. Son, E. J. Son, and K. H. Cho. 2005. Interactive effect of obesity indexes on cognition. Dement. Geriatr. Cogn. Disord. 19(2–3):91–96.PubMedCrossRef
34.
Elias, M. F., P. K. Elias, L. M. Sullivan, P. A. Wolf, and R. B. D’Agostino. 2005. Obesity, diabetes and cognitive deficit: the Framingham Heart Study. Neurobiol. Aging 26(1, Supplement 1):11–16 (Dec).PubMedCrossRef
35.
Cournot, M., J. C. Marquie, D. Ansiau, C. Martinaud, H. Fonds, J. Ferrieres, and J. B. Ruidavets. 2006. Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurol. 67(7):1208–1214 (Oct).CrossRef
36.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19):2486–2497 (May).
37.
Komulainen, P., T. A. Lakka, M. Kivipelto, M. Hassinen, E. L. Helkala, I. Haapala, A. Nissinen, and R. Rauramaa. 2007. Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women. Dement. Geriatr. Cogn. Disord. 23(1):29–34.PubMedCrossRef
38.
Yaffe, K., A. Kanaya, K. Lindquist, E. M. Simonsick, T. Harris, R. I. Shorr, F. A. Tylavsky, and A. B. Newman. 2004. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292(18):2237–2242 (Nov).PubMedCrossRef
39.
Dik, M. G., C. Jonker, H. C. Comijs, D. J. Deeg, A. Kok, K. Yaffe, and B. W. Penninx. 2007. Contribution of metabolic syndrome components to cognition in older persons. Diabetes Care 30:2655–2660 (Jun).PubMedCrossRef
40.
Kuo, H. K., C. J. Yen, C. H. Chang, C. K. Kuo, J. H. Chen, and F. Sorond. 2005. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 4(6):371–380 (Jun).PubMedCrossRef
41.
Bruehl, H., M. Rueger, I. Dziobek, V. Sweat, A. Tirsi, E. Javier, A. Arentoft, O. T. Wolf, and A. Convit. 2007. Hypothalamic–pituitary–adrenal axis dysregulation and memory impairments in Type 2 diabetes. J. Clin. Endocrinol. Metab. 92(7):2439–2445 (Jul).PubMedCrossRef
42.
Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. J. Am. Diet Assoc. 98(10):1178–1191 (Oct).
43.
Raz, N., K. M. Rodrigue, and J. D. Acker. 2003. Hypertension and the brain: vulnerability of the prefrontal regions and executive functions. Behav. Neurosci. 117(6):1169–1180 (Dec).PubMedCrossRef
44.
Lezak, M. D. 1995. Neuropsychological Assessment. 3rd ed. Oxford University Press, New York.
45.
Hamilton, M. 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23:56–62.PubMed
46.
Ansell, B., K. Watson, R. Weiss, and G. Fonarow. 2003. hsCRP and HDL Effects of Statins Trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. Heart Dis. 5:2–7.PubMedCrossRef
47.
Hanefeld, M., N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst. 2007. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J. Am. Coll. Cardiol. 49(3):290–297 (Jan).PubMedCrossRef
48.
Kinlay, S. 2007. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein. J. Am. Coll. Cardiol. 49(20):2003–2009.PubMedCrossRef
49.
Kritchevsky, S. B., M. Cesari, and M. Pahor. 2005. Inflammatory markers and cardiovascular health in older adults. Cardiovasc. Res. 66(2):265–275 (May).PubMedCrossRef
50.
Neisser, U., G. Boodoo, T. J. Bouchard, A. W. Boykin, N. Brody, S. J. Ceci, D. F. Halpern, J. C. Loehlin, R. Perloff, R. J. Sternberg, and S. Urbina. 1996. Intelligence: knowns and unknowns. Am. Psychol. 51(2):77–101 (Feb).CrossRef
51.
Barzilai, N., G. Atzmon, C. A. Derby, J. M. Bauman, and R. B. Lipton. 2006. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurol. 67:2170–2175.CrossRef
52.
Ramlawi, B., J. L. Rudolph, S. Mieno, J. Feng, M. Boodhwani, K. Khabbaz, S. E. Levkoff, E. R. Marcantonio, C. Bianchi, and F. W. Sellke. 2006. C-reactive protein and inflammatory response associated to neurocognitive decline following cardiac surgery. Surgery 140(2):221–226 (Aug).PubMedCrossRef
53.
Mathew, J. P., M. V. Podgoreanu, H. P. Grocott, W. D. White, R. W. Morris, M. Stafford-Smith, G. B. Mackensen, C. S. Rinder, J. A. Blumenthal, D. A. Schwinn, and M. F. Newman. 2007. Genetic variants in P-selectin and C-reactive protein influence susceptibility to cognitive decline after cardiac surgery. J. Am. Coll. Cardiol. 49(19):1934–1942 (May).PubMedCrossRef
54.
de Luca, C., and J. M. Olefsky. 2006. Stressed out about obesity and insulin resistance. Nat. Med. 12(1):41–42 (Jan).PubMedCrossRef
55.
Johnson, J. L., C. A. Slentz, B. D. Duscha, G. P. Samsa, J. S. McCartney, J. A. Houmard, and W. E. Kraus. 2004. Gender and racial differences in lipoprotein subclass distributions: the STRRIDE study. Atherosclerosis 176(2):371–377 (Oct).PubMedCrossRef
56.
Abdullah, S. M., A. Khera, D. Leonard, S. R. Das, R. M. Canham, S. A. Kamath, G. L. Vega, S. M. Grundy, D. K. McGuire, and J. A. de LemosSex differences in the association between leptin and CRP: results from the Dallas Heart Study. Atherosclerosis 195(2):404–410.PubMedCrossRef
57.
Molina, M. J., A. M. Mayor, A. E. Franco, C. A. Morell, M. A. Lopez, and L. M. Vila. 2007. Prevalence of systemic lupus erythematosus and associated comorbidities in Puerto Rico. J. Clin. Rheumatol. 13(4):202–204 (Aug).PubMedCrossRef
58.
Racial/ethnic differences in the prevalence and impact of doctor-diagnosed arthritis—United States, 2002. MMWR Morb Mortal Wkly Rep. 54(5):119–123 (Feb).
59.
Linares, L. F., J. J. Gomez-Reino, P. E. Carreira, L. Morillas, and I. Ibero. 1986. C-reactive protein (CRP) levels in systemic lupus erythematosus (SLE). Clin. Rheumatol. 5(1):66–69 (Jan).PubMedCrossRef
60.
Popkova, T. V., A. N. Khelkovskaia, E. S. Mach, E. N. Aleksandrova, A. A. Novikov, D. S. Novikova, and E. L. Nasonov. 2007. Cardiovascular diseases in rheumatoid arthritis. Ter. Arkh. 79(5):9–14.PubMed
61.
Urowitz, M. B., and D. D. Gladman. 2007. Atherosclerosis and lupus—the SLICC study. Lupus. 16(12):925–928.PubMedCrossRef
62.
Assous, N., E. Touze, C. Meune, A. Kahan, and Y. Allanore. 2007. Cardiovascular disease in rheumatoid arthritis: single-center hospital-based cohort study in France. Jt. Bone Spine 74(1):66–72 (Jan).CrossRef
63.
Shucard, J. L., J. J. Gaines, J. Ambrus Jr., and D. W. Shucard. 2007. C-reactive protein and cognitive deficits in systemic lupus erythematosus. Cogn. Behav. Neurol. 20(1):31–37 (Mar).PubMedCrossRef
64.
Nandula, S. R., S. Amarnath, A. Molinolo, B. C. Bandyopadhyay, B. Hall, C. M. Goldsmith, C. Zheng, J. Larsson, T. Sreenath, W. Chen, I. S. Ambudkar, S. Karlsson, B. J. Baum, and A. B. Kulkarni. 2007. Female mice are more susceptible to developing inflammatory disorders due to impaired transforming growth factor beta signaling in salivary glands. Arthritis Rheum. 56(6):1798–1805 (Jun).PubMedCrossRef
65.
Pradhan, A. D., J. E. Manson, J. E. Rossouw, D. S. Siscovick, C. P. Mouton, N. Rifai, R. B. Wallace, R. D. Jackson, M. B. Pettinger, and P. M. Ridker. 2002. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative observational study. JAMA 288(8):980–987 (Aug).PubMedCrossRef
66.
Singh, U., S. Devaraj, J. Vasquez-Vivar, and I. Jialal. 2007. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J. Mol. Cell Cardiol. 43(6):780–791 (Dec).PubMedCrossRef
67.
Jialal, I., S. Devaraj, and S. K. Venugopal. 2004. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44(1):6–11 (Jul).PubMedCrossRef
68.
Verma, S., C. H. Wang, S. H. Li, A. S. Dumont, P. W. Fedak, M. V. Badiwala, B. Dhillon, R. D. Weisel, R. K. Li, D. A. Mickle, and D. J. Stewart. 2002. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106(8):913–919 (Aug).PubMedCrossRef
69.
Schmidt, R., C. Enzinger, S. Ropele, H. Schmidt, and F. Fazekas. 2006. Subcortical vascular cognitive impairment: Similarities and differences with multiple sclerosis. J. Neurol. Sci. 245(1–2):3–7 (Jun).PubMedCrossRef
70.
Gold, S. M., I. Dziobek, K. Rogers, A. Bayoumy, P. F. McHugh, and A. Convit. 2005. Hypertension and hypothalamo–pituitary–adrenal axis hyperactivity affect frontal lobe integrity. J. Clin. Endocrinol. Metab. 90(6):3262–3267 (Jun).PubMedCrossRef
71.
Raz, N., K. M. Rodrigue, and J. D. Acker. 2003. Hypertension and the brain: vulnerability of the prefrontal regions and executive functions. Behav. Neurosci. 117(6):1169–1180 (Dec).PubMedCrossRef
72.
van Dijk, E. J., N. D. Prins, S. E. Vermeer, H. A. Vrooman, A. Hofman, P. J. Koudstaal, and M. M. B. Breteler. 2005. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 112(6):900–905 (Aug).PubMedCrossRef
Metadata
Title
C-Reactive Protein is Linked to Lower Cognitive Performance in Overweight and Obese Women
Authors
V. Sweat
V. Starr
H. Bruehl
A. Arentoft
A. Tirsi
E. Javier
A. Convit
Publication date
01-06-2008
Publisher
Springer US
Published in
Inflammation / Issue 3/2008
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-008-9065-3

Other articles of this Issue 3/2008

Inflammation 3/2008 Go to the issue

OriginalPaper

Spermine and Endothelial Damage During Endotoxemia

OriginalPaper

Serum Pro-hepcidin Levels in Rheumatoid Arthritis and Systemic Lupus Erythematosus

OriginalPaper

Anti-inflammatory Effects of Ethanol Extract from Kummerowia striata (Thunb.) Schindl on LPS-Stimulated RAW 264.7 Cell

OriginalPaper

IL-17 Producing γδ T Cells are Required for a Controlled Inflammatory Response after Bleomycin-induced Lung Injury

OriginalPaper

Low Level Laser Therapy (LLLT) Decreases Pulmonary Microvascular Leakage, Neutrophil Influx and IL-1β Levels in Airway and Lung from Rat Subjected to LPS-Induced Inflammation

OriginalPaper

Dehydroepiandrosterone and Dehydroepiandrosterone Sulphate in Atopic Allergy and Chronic Urticaria
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits